Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
Delayed Nasdaq  -  04:00 2022-09-29 pm EDT
264.28 USD   -4.46%
10:44aOppenheimer Adjusts Biogen Price Target to $300 From $230, Maintains Outperform Rating
MT
05:21aNorth American Morning Briefing: Stock Futures -2-
DJ
04:43aEisai Shares Skyrocket 14% on Favorable Results of Alzheimer's Drug
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

U.S. FDA grants priority review to Biogen's ALS drug

07/26/2022 | 08:12am EDT
FILE PHOTO: Illustration shows Biogen logo

(Reuters) - U.S. Food and Drug Administration granted priority review to Biogen Inc's experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS), the drugmaker said on Tuesday.

Biogen licensed the treatment, tofersen, from Ionis Pharmaceuticals Inc.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. -4.46% 264.28 Delayed Quote.10.15%
IONIS PHARMACEUTICALS, INC. -0.32% 44.28 Delayed Quote.45.51%
All news about BIOGEN INC.
10:44aOppenheimer Adjusts Biogen Price Target to $300 From $230, Maintains Outperform Rating
MT
05:21aNorth American Morning Briefing: Stock Futures -2-
DJ
04:43aEisai Shares Skyrocket 14% on Favorable Results of Alzheimer's Drug
MT
03:35aDrug will 'change landscape of Alzheimer's treatment'
RE
01:10aTrending : Eisai Shares Rise After Alzheimer's Drug Shows Promise
DJ
09/28Japan's Nikkei tracks Wall Street higher as Treasury yields fall
RE
09/28Health Care Up as Biogen Surges -- Health Care Roundup
DJ
09/28US Stocks Climb Wednesday, Yields Slump After Bank of England Move
MT
09/28US Stocks Climb Wednesday Following Bank of England Move
MT
09/28Biogen's Latest Data for Alzheimer's Drug Raises Likelihood for Approval, May Lead to '..
MT
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2022 10 007 M - -
Net income 2022 2 340 M - -
Net cash 2022 11,0 M - -
P/E ratio 2022 16,3x
Yield 2022 -
Capitalization 38 350 M 38 350 M -
EV / Sales 2022 3,83x
EV / Sales 2023 3,75x
Nbr of Employees 9 610
Free-Float 85,1%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Last Close Price 264,28 $
Average target price 266,65 $
Spread / Average Target 0,90%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Alphonse Galdes EVP-Pharmaceutical Operations & Technology
Mahalakshmi Radhakrishnan Chief Medical Officer & Group Senior VP
Sector and Competitors
1st jan.Capi. (M$)
BIOGEN INC.10.15%40 140
CSL LIMITED-2.88%88 263
SAMSUNG BIOLOGICS CO.,LTD.-9.97%38 103
WUXI BIOLOGICS (CAYMAN) INC.-47.76%26 271
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-29.98%18 759
BIOMARIN PHARMACEUTICAL INC.-3.72%15 921